

University of Groningen

Trajectories of renal biomarkers and new-onset heart failure in the general population

Sakaniwa, Ryoto; Tromp, Jasper; Streng, Koen W; Suthahar, Navin; Kieneker, Lyanne M; Postmus, Douwe; Iso, Hiroyasu; Gansevoort, Ron T; Bakker, Stephan J L; Hillege, Hans L

Published in:
European Journal of Heart Failure

DOI:
[10.1002/ejhf.2925](https://doi.org/10.1002/ejhf.2925)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2023

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Sakaniwa, R., Tromp, J., Streng, K. W., Suthahar, N., Kieneker, L. M., Postmus, D., Iso, H., Gansevoort, R. T., Bakker, S. J. L., Hillege, H. L., de Boer, R. A., & Demissei, B. G. (2023). Trajectories of renal biomarkers and new-onset heart failure in the general population: Findings from the PREVEND study. *European Journal of Heart Failure*, 25(7), 1072-1079. <https://doi.org/10.1002/ejhf.2925>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Trajectories of renal biomarkers and new-onset heart failure in the general population: Findings from the PREVEND study

Ryoto Sakaniwa^{1,2}, Jasper Tromp^{1,3,4*}, Koen W. Streng¹, Navin Suthahar¹, Lyanne M. Kienerker⁵, Douwe Postmus¹, Hiroyasu Iso^{2,6}, Ron T. Gansevoort⁵, Stephan J.L. Bakker⁵, Hans L. Hillege¹, Rudolf A. de Boer¹, and Biniyam G. Demissei^{1,7}

¹Department of Cardiology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands; ²Public Health, Department of Social Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan; ³Saw Swee Hock School of Public Health, National University of Singapore & National University Health System, Singapore, Singapore; ⁴Duke-NUS Medical School, Singapore, Singapore; ⁵Division of Nephrology, Department of Internal Medicine, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands; ⁶The Institute for Global Health Policy, National Center for Global Health and Medicine, Tokyo, Japan; and ⁷Division of Cardiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Received 8 February 2022; revised 27 May 2023; accepted 1 June 2023; online publish-ahead-of-print 4 July 2023

Aims

Renal dysfunction is one of the most critical risk factors for developing heart failure (HF). However, the association between repeated measures of renal function and incident HF remains unclear. Therefore, this study investigated the longitudinal trajectories of urinary albumin excretion (UAE) and serum creatinine and their association with new-onset HF and all-cause mortality.

Methods and results


Using group-based trajectory analysis, we estimated trajectories of UAE and serum creatinine in 6881 participants from the Prevention of Renal and Vascular End-stage Disease (PREVEND) study and their association with new-onset HF and all-cause death during the 11-years of follow-up. Most participants had stable low UAE or serum creatinine. Participants with persistently higher UAE or serum creatinine were older, more often men, and more often had comorbidities, such as diabetes, a previous myocardial infarction or dyslipidaemia. Participants with persistently high UAE had a higher risk of new-onset HF or all-cause mortality, whereas stable serum creatinine trajectories showed a linear association for new-onset HF and no association with all-cause mortality.

Conclusion

Our population-based study identified different but often stable longitudinal patterns of UAE and serum creatinine. Patients with persistently worse renal function, such as higher UAE or serum creatinine, were at a higher risk of HF or mortality.

*Corresponding author. 12 Science Drive 2, #10-01, Singapore 117549, Singapore. Tel: +65 6516 4988, Email: jasper_tromp@nus.edu.sg
Ryoto Sakaniwa and Jasper Tromp Contributed equally as first authors.

Graphical Abstract



In the PREVEND study, distinct temporal patterns of renal biomarkers among European adults were identified. High urinary albumin excretion (UAE) or creatinine levels, often stable over time, were associated with new-onset heart failure.

Keywords

Urinary albumin excretion • Serum creatinine • Longitudinal trajectory of renal biomarkers • New-onset heart failure • Cardio-renal interactions • Microalbuminuria

Introduction

One in five men and women will develop heart failure (HF) during their lifetime.^{1–6} While progress has been made in treating HF, prognosis remains poor, with nearly half of patients dying within 5 years.⁷ Therefore, primary prevention of HF is critical.

Substantial evidence supports the association between renal dysfunction and major cardiovascular disease,⁸ including new-onset HF.^{9–11} Previous reports showed the association of biomarkers reflecting renal dysfunction, such as urinary albumin excretion (UAE), serum creatinine and cystatin C, with incident HF.^{10,12} However, how longitudinal changes in renal biomarkers are associated with incident HF or mortality remain unclear.^{13–15}

The Prevention of Renal and Vascular End-stage Disease (PREVEND) study was designed to assess the prevalence of microalbuminuria and its association with new-onset cardiovascular disease in the population.¹⁶ We hypothesized that longitudinal patterns of UAE and creatinine were associated with new-onset HF or all-cause mortality in the general population. Therefore, this study estimated possible causal trajectories of creatinine and UAE and their association with incident HF.

Methods

Study population

This study was performed using data from the PREVEND study. The PREVEND study recruited the general Dutch population in the

North of the Netherlands aged 28–75 years during a baseline visit in 1997–1998.^{10,16} For this study, we included 6904 participants from the original 8592 participants based on the availability of either UAE or creatinine at baseline and during at least one follow-up visit. We excluded 23 participants who had HF at baseline. Thus, 6881 individuals were included in recent analyses ($n = 6799$ for UAE, 6841 for serum creatinine, and 6737 for a combination of UAE/serum creatinine). The PREVEND study was approved by the institutional medical Ethics Committee and conducted as per the Declaration of Helsinki. All subjects provided written informed consent.

Definitions

Participants were asked to collect two consecutive 24 h urine samples for baseline, second, and third screenings of UAE, of which we took the mean. Urinary albumin concentration was determined by nephelometry, with a threshold of 2.3 mg/L and intra- and inter-assay coefficients of variation of 2.2% and 2.6%, respectively (BNII, Dade Behring Diagnostics, Marburg, Germany). Serum creatinine was measured by dry chemistry (Eastman Kodak, Rochester, NY, USA), with an intra-assay coefficient of variation of 0.9% and an inter-assay coefficient of variation of 2.9%. We analysed UAE and creatinine measurements at baseline and during two follow-up visits at 3–4 years and 6–7 years after baseline.

Systolic and diastolic blood pressures were calculated as the mean of the last two measurements of the two visits using an automatic Dinamap XL Model 9300 series device. Hypertension was defined as systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg, or self-reported use of antihypertensive medication. Body mass index was calculated as the weight to height squared (kg/m^2) ratio. Dyslipidaemia was defined as total serum

cholesterol ≥ 6.5 mmol/L (251 mg/dl) or serum cholesterol ≥ 5.0 mmol/L (193 mg/dl) if a history of myocardial infarction was present or when lipid-lowering medication was used. Statin use was defined by self-report. Type 2 diabetes was defined as fasting plasma glucose ≥ 7.0 mmol/L (126 mg/dl), non-fasting plasma glucose ≥ 11.1 mmol/L or use of anti-diabetic drugs. Plasma glucose and serum cholesterol were determined by Kodak Ektachem dry chemistry (Eastman Kodak). High-sensitivity C-reactive protein was determined by nephelometry with a threshold of 0.175 mg/L and an intra- and inter-assay coefficient of less than 4.4% and 5.7%, respectively (BNiIN). N-terminal pro-B-type natriuretic peptide (NT-proBNP) was measured with Elecsys™ 2010, with an intra- and inter-assay coefficient of variation of 1.2–1.5% and 4.4–5.0%, respectively (Roche Diagnostics, Mannheim, Germany). High-sensitivity troponin T (hs-TnT) was measured using modular analytics serum work areas, with a 10% coefficient of variation at the 99th percentile of the reference range (Roche Diagnostics).

Definition for new-onset heart failure and mortality

Briefly, participants were censored at the date they moved to an unknown location or the last follow-up date (1st January 2010), whatever came first. Dates and causes of death for every participant were obtained from national death registries of the Netherlands and coded according to the 10th revision of the International Classification of Diseases.¹⁷

The definition of new-onset HF was described previously.¹⁰ New-onset HF was identified using criteria following the European Society of Cardiology guidelines.^{18,19} Two experts validated each case by reviewing anonymized clinical charts, hospitalization, and physician office records to ascertain the incidence of HF. In case of a difference of opinion about an individual case, the committee made a joint decision.^{18,19} The aetiology and the date of onset of HF were derived from clinical charts. The local Ethics Committees of both hospitals granted permission to access hospital records.

Statistical analysis

Latent class growth modelling was used to identify distinct UAE and creatinine trajectories.²⁰ We used the lowest Bayesian information criterion (BIC) value to select the optimal number of trajectories. The BIC is commonly used to select the correct number of trajectories^{21–23} and was found to be as valid as, for example, the likelihood ratio test or the Lo–Mendell–Rubin test.²⁴ Baseline characteristics were presented to individual patient subgroups based on the latent class growth modelling. Continuous variables were presented as mean (standard deviation), median (interquartile range) or number (percentage), depending on the nature and distribution of the variable. Differences in baseline characteristics between subgroups were tested using the one-way analysis of variance (ANOVA), Kruskal–Wallis test, or Chi-square test, depending on the nature and distribution of the variable. Cause-specific hazards modelling was utilized to determine the associations between UAE and serum creatinine trajectories and subsequent risk of HF or all-cause mortality. We used cause-specific hazard models, which are considered valid in the presence of competing risks.²⁵ Weighted cause-specific hazard models were used to account for the over-selection of participants with elevated UAE in the PREVEND study as described previously.¹⁰ The exposure variables were modelled as factor (group) variables using the trajectory with the lowest absolute risk (risk nadir) as the reference. Confounders in the model were selected based on clinical

relevance and significant differences between trajectories. To estimate outcomes, we used a landmark analysis-based approach. This means that the time to event was estimated using the date of the last known creatinine or UAE measurement as the baseline. We used case-wise deletion for multivariable models leading to a total of 6193 (91%) out of 6799 participants with repeated UAE measurements included and 6148 (95%) out of 6481 participants with repeated creatinine included. Confounders were chosen based on clinical relevance and previous publications.¹⁰ We estimated to variance inflation factor (VIF) to evaluate the possible collinearity of confounders and found that the VIF was < 5.0 for all included variables. Due to the low missingness of confounders, we did not consider multiple imputations for our analyses. We tested the possible modifying effect of sex on the association between trajectories and incident HF or all-cause mortality by performing an interaction test. A p -value < 0.05 (two-sided) was defined as statistically significant. All analyses were performed using R 3.4.0 (R Foundation for Statistical Computing, Vienna, Austria).

Results

Longitudinal urinary albumin excretion and creatinine trajectories and baseline characteristics

Online supplementary Table S1 shows that the BIC for different latent class growth models was lowest for eight UAE (Figure 1A) and ten creatinine trajectories (Figure 1B).

Table 1 shows the baseline characteristics according to UAE trajectories, and Table 2 shows the baseline characteristics according to creatinine trajectories. Participants with increasing or stable high UAE and creatinine trajectories were generally older, more often men had higher systolic and diastolic blood pressure and a higher prevalence of previous myocardial infarction, diabetes, dyslipidaemia, or antihypertensive medication use. Furthermore, those with persistently high UAE or creatinine had higher high-sensitivity C-reactive protein, NT-proBNP and hs-TnT concentrations.

The association between renal biomarker trajectories and outcomes

During a median follow-up of 11.5 years, 278 (4.1%) participants developed HF and 281 (4.1%) participants died.

Table 3 shows the associations between UAE trajectories, incident HF, and UAE trajectories and mortality. The group of patients with the persistently lowest UAE concentrations (Trajectory 1) was used as the reference category since they were at the lowest risk of incident HF or mortality. The hazard ratio (HR) for incident HF ranged from 0.92 (95% confidence interval [CI] 0.77–1.10) for Trajectory 2 to 5.99 (95% CI 3.74–9.61) for Trajectory 7. After adjustments for confounders, persistently elevated UAE (Trajectory 6: HR 1.41, 95% CI 1.00–1.98; and Trajectory 7: HR 1.63, 95% CI 1.01–2.64) remained at a higher risk for incident HF than participants with consistently low UAE (Trajectory 1). The association of trajectories with all-cause mortality followed similar patterns. The HR ranged from 1.42 (95% CI 1.22–1.64) for Trajectory 2 to 11.0 (95% CI 7.9–15.4) for Trajectory 7. After correcting




Figure 1 The time-dependent trajectories for urinary albumin excretion (UAE) (A) and serum creatinine (B). Both UAE and serum creatinine concentrations are shown on a natural logarithmic scale. The percentages reflect the proportion of the population represented by each class trajectory. The lowest Bayesian information criterion value was used to select the optimal number of trajectories.

for confounders, Trajectories 2, 7, and 8 remained at a higher risk for mortality than Trajectory 1.

Table 4 shows the associations between creatinine trajectories, incident HF, and creatinine trajectories and mortality. The HRs for incident HF ranged from 0.93 (95% CI 0.41–2.10) to 12.85 (95% CI 3.44–47.97). After adjustment for confounders, Trajectories 6, 7 and 8 were associated with a higher risk for HF. None of the trajectories were associated with an increased mortality risk compared to Trajectory 1 in the fully adjusted analyses. Sex did not modify the association between any of the trajectories (UAE, creatinine) and all-cause mortality or incident HF ($p_{\text{interaction}} \geq 0.2$ for all).

Discussion

This study identified distinct UAE and serum creatinine trajectories in a large, well described population-based cohort. Longitudinal UAE and serum creatinine trajectories largely remained stable for 11-year follow-up. Participants with persistently higher UAE or creatinine trajectories were more likely to develop new-onset HF or die (*Graphical Abstract*).

Previous studies demonstrated a robust association between increased UAE or serum creatinine levels and incident HF or death.^{10,12,26,27} However, few studies investigated longitudinal UAE or serum creatinine patterns. Longitudinal UAE and serum creatinine trajectories were stable over time in our study. A study in the Coronary Artery Risk Development in Young Adults (CARDIA) cohort identified five trajectory groups of urinary albumin-to-creatinine ratio (UACR).²⁸ In this previous study, most participants had low-stable, moderate-stable, or high-stable UACR between the year 10 and year 30 examinations.²⁸ In CARDIA, those with high-stable UACR were more likely Black and had a history of hypertension.²⁸ Our results are similar to those in CARDIA, such that most participants had stable UAE or serum creatinine over time and those with worse-stable renal function markers were older and more often used antihypertensive medication. Our results extend on the CARDIA study results by including a relatively older population and a larger sample size.

Participants with persistently high UAE or creatinine had a higher risk of adverse outcomes. Previous studies in PREVENT or the Framingham Heart Study demonstrated the association of cross-sectional UAE or serum creatinine with incident HF and mortality.^{10,29} In the previous study from CARDIA, participants with high-stable UACR had a higher left ventricular mass and worse longitudinal strain.²⁸ Our results extend on these previous studies by demonstrating the association of persistently high worse renal function with incident HF and mortality. These associations were robust after correction for confounders.

The association between a decreasing UAE trajectory (Trajectory 5) and incident HF was not statistically significant. However, these participants constituted only 2.1%. Therefore, the analyses for this trajectory were likely underpowered to show a meaningful difference. The association between UAE trajectories and incident HF or mortality appeared to be linear. The substantial differences between our unadjusted and adjusted analyses, highlighted the significant confounding effects of, among others, age, sex and medical history. There was a less strong stepwise relationship of serum creatinine trajectories with mortality than for UAE in the fully adjusted model. This highlights that UAE is a stronger predictor of mortality than serum creatinine. UAE is a marker of renal dysfunction. Patients with renal dysfunction have high fibroblast growth factor 23 (FGF23) concentrations.⁹ Increased concentrations of FGF23 might cause endothelial dysfunction, leading to HF.^{9,30} In severe renal dysfunction, the accumulation of toxins through impaired renal clearance might cause direct cardiac muscle inflammation and HF.⁹ Blood pressure trajectories might have influenced our results. In the SPRINT trial, estimated glomerular filtration rate and UAE were strong predictors of incident HF but did not modify the effect of intensive blood pressure control in decreasing HF risk.³¹ Furthermore, medication initiated during follow-up, for which we could not account, might have influenced the trajectories and their association with incident HF or all-cause mortality.

Together, our results suggest that opportunities for interventions to reduce UAE further exist in this particular subgroup. A

Table 1 Baseline characteristics according to urinary albumin excretion trajectory

	Urinary albumin excretion								p-value
	Trajectory 1	Trajectory 2	Trajectory 3	Trajectory 4	Trajectory 5	Trajectory 6	Trajectory 7	Trajectory 8	
No. at risk	2187	2439	1105	503	145	273	104	43	
Age, years	51.3 (11.2)	51.7 (11.8)	54.6 (12.1)	59.6 (11.8)	56.5 (12.8)	60.7 (11.4)	63.3 (11.3)	60.6 (13.5)	<0.001
Male sex, %	36.6	50.9	57.3	66	52.4	72.2	74	72.1	<0.001
BMI, kg/m ²	25.3 (3.8)	25.7 (4.0)	26.7 (4.3)	27.2 (4.1)	26.5 (4.6)	28.1 (4.6)	28.6 (4.1)	29.3 (4.7)	<0.001
Systolic BP, mmHg	121.7 (16.5)	127.3 (18.6)	131.7 (18.9)	136.6 (20.5)	139.2 (25.8)	143.3 (22.0)	144.6 (20.6)	148.3 (25.2)	<0.001
Diastolic BP, mmHg	70.8 (8.3)	73.4 (9.5)	75.5 (9.4)	77.8 (9.5)	79.1 (12.6)	80.2 (9.9)	79.2 (8.8)	81.4 (10.7)	0.07
Myocardial infarction, %	1.3	1.2	3.3	6.6	6.9	5.9	12.5	11.6	<0.001
Diabetes mellitus, %	0.5	0.9	1.4	9.4	3.4	2.2	5.8	9.3	<0.001
Dyslipidaemia or statin use, %	2.7	3.0	5.8	9.4	7.2	8.8	16.0	14.3	<0.001
Antihypertensive medication use, %	11.1	11.5	17.8	27.4	20.2	30.3	45.6	44.4	<0.001
Hs-C-reactive protein, mg/L	1.0 (0.5–2.4)	1.1 (0.5–2.5)	1.4 (0.6–3.2)	1.8 (0.9–4.0)	2.5 (1.0–6.4)	2.2 (0.9–4.0)	2.8 (1.3–6.2)	2.3 (1.2–4.1)	<0.001
NT-proBNP, ng/L	36.4 (17.4–68.1)	33.8 (15.0–65.1)	35.5 (15.2–68.1)	35.5 (15.8–86.1)	58.0 (27.6–109.7)	42.7 (18.6–91.9)	60.4 (26.1–160.8)	69.2 (17.4–171.2)	<0.001
Hs-TnT, ng/L	2.5 (2.5–3.0)	2.5 (2.5–4.0)	3.0 (2.5–5.0)	4.0 (2.5–7.0)	2.5 (2.5–6.0)	5.0 (3.0–8.0)	7.0 (3.0–11.0)	7.0 (2.5–10.0)	<0.001

BMI, body mass index; BP, blood pressure; hs, high-sensitivity; hs-TnT, high-sensitivity troponin T; NT-proBNP, N-terminal pro-B-type natriuretic peptide.

The lowest Bayesian information criterion value was used to select the optimal number of trajectories.

Table 2 Baseline characteristics according to serum creatinine trajectory

	Serum creatinine										p-value
	Trajectory 1	Trajectory 2	Trajectory 3	Trajectory 4	Trajectory 5	Trajectory 6	Trajectory 7	Trajectory 8	Trajectory 9/10		
No. at risk	144	812	1564	1750	1524	787	188	56	16		
Age, years	54.3 (11.6)	53.6 (11.1)	51.4 (11.2)	50.8 (11.8)	52.9 (12.3)	53.9 (12.3)	56.1 (10.6)	64.8 (7.7)	70.5 (11.8)		<0.001
Male sex, %	2.1	5.9	20.1	51.0	78.8	90.9	92.6	92.9	68.8		<0.001
BMI, kg/m ²	26.4 (5.4)	26.2 (4.9)	25.6 (4.4)	25.6 (4.0)	25.9 (3.8)	26.3 (3.2)	26.7 (3.2)	27.4 (3.3)	27.4 (4.5)		0.926
Systolic BP, mmHg	132.5 (20.8)	127 (18.9)	122.3 (18.6)	123.4 (18.6)	127.2 (18.3)	130.9 (19.1)	135.6 (22.3)	145 (22.0)	149.2 (22.6)		<0.001
Diastolic BP, mmHg	74.9 (8.6)	72.0 (8.9)	70.4 (8.9)	71.4 (9.2)	73.4 (9.2)	75.3 (9.8)	77.7 (10.3)	81.5 (11.1)	83.5 (7.3)		<0.001
Myocardial infarction, %	0.0	0.7	0.6	2.2	3.1	4.7	10.1	19.6	25.0		<0.001
Diabetes mellitus, %	2.8	1.6	0.8	1.1	1.4	1.4	2.7	3.6	6.3		<0.001
Dyslipidaemia or statin use, %	5.1	2.4	2.3	4.1	4.9	6.5	13.6	18.9	20.0		<0.001
Antihypertensive medication use, %	16.0	11.3	10.1	12.7	16.6	22.3	42.4	60.8	87.5		<0.001
Hs-C-reactive protein, mg/L	1.8 (0.6–4.9)	1.2 (0.5–3.1)	1.2 (0.5–2.9)	1.1 (0.5–2.7)	1.2 (0.5–2.7)	1.3 (0.6–2.7)	1.9 (0.9–4.2)	2.2 (1.4–3.8)	2.4 (1.1–5.1)		<0.001
NT-proBNP, ng/L	52.9 (25.1–77.3)	44.4 (24.5–80.1)	42.8 (22.8–73.8)	33.9 (15.5–65.0)	27.7 (12.1–60.5)	26.2 (9.8–60.4)	62.3 (23.0–172.5)	121.1 (47.6–299.1)	250.3 (121.6–355.7)		<0.001
Hs-TnT, ng/L	2.5 (2.5–2.5)	2.5 (2.5–2.5)	2.5 (2.5–3.0)	3.0 (2.5–5.0)	4.0 (2.5–6.0)	7.0 (4.0–10.0)	7.0 (4.0–10.0)	11.0 (7.0–16.0)	12.0 (6.0–15.0)		<0.001

BMI, body mass index; BP, blood pressure; hs, high-sensitivity; hs-TnT, high-sensitivity troponin T; NT-proBNP, N-terminal pro-B-type natriuretic peptide.

The lowest Bayesian information criterion value was used to select the optimal number of trajectories.

Table 3 Associations between urinary albumin excretion trajectories and outcomes

Urinary albumin excretion		Trajectory 1	Trajectory 2	Trajectory 3	Trajectory 4	Trajectory 5	Trajectory 6	Trajectory 7	Trajectory 8
No. at risk		2187	2440	1105	503	145	273	104	43
Person-years		24185	27008	12186	5477	1610	3031	1062	451
Heart failure									
No. of incident		45	59	62	41	11	36	18	6
Unadjusted HR (95% CI)	Ref		0.92 (0.77–1.10)	1.62 (1.30–2.02)	3.17 (2.39–4.21)	2.32 (1.34–4.01)	5.34 (3.90–7.29)	5.99 (3.74–9.61)	4.13 (1.92–8.92)
Adjusted HR (95% CI)	Ref		0.82 (0.68–0.98)	0.81 (0.63–1.04)	1.35 (1.01–1.81)	0.97 (0.56–1.70)	1.41 (1.00–1.98)	1.63 (1.01–2.64)	1.14 (0.52–2.50)
All-cause mortality									
No. of incident		41	72	58	45	8	22	23	8
Unadjusted HR (95% CI)	Ref		1.42 (1.22–1.64)	2.53 (2.12–3.02)	3.70 (2.91–4.69)	2.01 (1.16–3.48)	3.53 (2.51–4.96)	11.03 (7.90–15.40)	8.85 (5.12–15.31)
Adjusted HR (95% CI)	Ref		1.19 (1.02–1.38)	1.30 (1.07–1.56)	1.22 (0.94–1.57)	0.87 (0.48–1.57)	0.95 (0.66–1.36)	2.58 (1.81–3.68)	2.03 (1.16–3.56)

CI, confidence interval; HR, hazard ratio. Adjusted HRs were adjusted for age, sex, body mass index, systolic blood pressure, myocardial infarction, diabetes mellitus, hypercholesterolaemia or statin use and antihypertensive medication use. The lowest Bayesian information criterion value was used to select the optimal number of trajectories.

Table 4 Associations between serum creatinine trajectories and outcomes

Serum creatinine		Trajectory 1	Trajectory 2	Trajectory 3	Trajectory 4	Trajectory 5	Trajectory 6	Trajectory 7	Trajectory 8	Trajectory 9/10
No. at risk		144	812	1564	1750	1524	787	188	56	16
Person-years		1583	8985	17283	19410	16800	8611	2023	584	162
Heart failure										
No. of incident		5	19	38	57	69	48	30	9	3
Unadjusted HR (95% CI)	Ref		0.93 (0.41–2.10)	1.51 (0.69–3.29)	1.66 (0.77–3.61)	2.01 (0.93–4.36)	3.24 (1.15–7.07)	7.06 (3.15–15.82)	12.77 (5.36–30.43)	12.85 (3.44–47.97)
Adjusted HR (95% CI)	Ref		1.06 (0.46–2.45)	2.20 (1.00–4.80)	2.06 (0.94–4.50)	1.97 (0.90–4.50)	2.64 (1.19–5.84)	2.65 (1.15–6.11)	3.29 (1.35–7.97)	2.63 (0.70–9.95)
All-cause mortality										
No. of incident		4	29	36	50	72	48	24	11	4
Unadjusted HR (95% CI)	Ref		0.71 (0.47–1.07)	0.48 (0.32–0.72)	0.48 (0.32–0.72)	0.79 (0.53–1.17)	0.93 (0.62–1.40)	2.15 (1.38–3.35)	3.84 (2.27–6.50)	5.73 (2.45–13.38)
Adjusted HR (95% CI)	Ref		0.98 (0.65–1.50)	0.52 (0.15–1.81)	0.37 (0.10–1.30)	0.39 (0.11–1.44)	0.38 (0.10–1.46)	0.41 (0.10–1.66)	0.46 (0.01–2.21)	0.60 (0.11–3.20)

CI, confidence interval; HR, hazard ratio. Adjusted HRs were adjusted for age, sex, body mass index, systolic blood pressure, myocardial infarction, diabetes mellitus, hypercholesterolaemia or statin use and antihypertensive medication use. The lowest Bayesian information criterion value was used to select the optimal number of trajectories.

study in SAVOR-TIMI 53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients With Diabetes Mellitus-Thrombolysis in Myocardial Infarction 53) identified estimated glomerular filtration rate and UACR among the five most important risk factors for incident HF.^{28,32} Importantly, participants at a higher risk for HF derived more benefit from treatment with sodium–glucose cotransporter 2 (SGLT2) inhibitors.³² Therefore, people with higher stable UAE might benefit from SGLT2 inhibitors.

Limitations

The results of our study are best valued in light of several limitations. First, the PREVEND study only included Caucasian participants, preventing extrapolation to other ethnic groups. Furthermore, the observational nature of our study excludes causal estimation. HF was determined by chart review, possibly leading to under-detection of cases. Previously, cystatin C was found to be an important predictor of new-onset HF in PREVEND.¹⁰ Unfortunately, we did not have repeated cystatin C measurements, therefore, we could not estimate cystatin C trajectories. Our analyses did not enable us to identify a clinically meaningful difference for UAE or creatinine. We could not analyse HF subclasses (e.g. HF with reduced or preserved ejection fraction) due to limited statistical power. Unfortunately, we could not account for the type of antihypertensive medication. The current study findings might not generalize to the modern era of guideline-directed medical therapy, including the use of SGLT2 inhibitors and angiotensin receptor–neprilysin inhibitors.

Conclusion

This study identified the population's distinct temporal patterns for UAE and serum creatinine. High levels of UAE or creatinine, which were often stable over time, were associated with greater risk for new-onset HF and all-cause mortality, suggesting that interventions targeted at reducing UAE might benefit these subgroups.

Supplementary Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Acknowledgements

We thank the member of the Prevention of Renal and Vascular End-stage Disease (PREVEND) study. This study was technically supported by the Advanced Clinical Epidemiology Investigator's Research Project at Osaka University Graduate School of Medicine.

Funding

This study was financially supported by grant E.013 of the Dutch Kidney Foundation (Nier Stichting Nederland) and by a grant from Bristol-Myers Squibb. Dr. Tromp is supported by the National University of Singapore

Start-up grant, the tier 1 grant from the Ministry of Education and the CS-IRG New Investigator Grant from the National Medical Research Council.

Conflict of interest: J.T. has received consulting or speaker fees from Daiichi-Sankyo, Boehringer Ingelheim, Roche Diagnostics and Us2.ai, owns patent US-10702247-B2 unrelated to the present work. All other authors have nothing to disclose.

References

- Savarese G, Lund LH. Global public health burden of heart failure. *Card Fail Rev*. 2017;3:7–11. <https://doi.org/10.15420/cfr.2016.25.2>
- Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. *Eur J Heart Fail*. 2020;22:1342–1356. <https://doi.org/10.1002/ehf.1858>
- Tsao CW, Aday AW, Almarazoo ZI, Alonso A, Beaton AZ, Bittencourt MS, et al. Heart disease and stroke statistics – 2022 update: A report from the American Heart Association. *Circulation*. 2022;145:e153–e639. <https://doi.org/10.1161/CIR.0000000000001052>
- Khan SS, Ning H, Shah SJ, Yancy CW, Carnethon M, Berry JD, et al. 10-year risk equations for incident heart failure in the general population. *J Am Coll Cardiol*. 2019;73:2388–2397. <https://doi.org/10.1016/j.jacc.2019.02.057>
- Tromp J, Ferreira JP, Janwanishstaporn S, Shah M, Greenberg B, Zannad F, et al. Heart failure around the world. *Eur J Heart Fail*. 2019;21:1187–1196. <https://doi.org/10.1002/ehf.1585>
- Tromp J, Bamadhaj S, Cleland JGF, Angermann CE, Dahlstrom U, Ouwerkerk W, et al. Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): A cohort study. *Lancet Glob Health*. 2020;8:e411–e422. [https://doi.org/10.1016/S2214-109X\(20\)30004-8](https://doi.org/10.1016/S2214-109X(20)30004-8)
- Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: An individual patient data meta-analysis. *Eur Heart J*. 2012;33:1750–1757. <https://doi.org/10.1093/eurheartj/ehr254>
- Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular disease in chronic kidney disease. *Circulation*. 2021;143:1157–1172. <https://doi.org/10.1161/CIRCULATIONAHA.120.050686>
- ter Maaten JM, Damman K, Verhaar MC, Paulus WJ, Duncker DJ, Cheng C, et al. Connecting heart failure with preserved ejection fraction and renal dysfunction: The role of endothelial dysfunction and inflammation. *Eur J Heart Fail*. 2016;18:588–598. <https://doi.org/10.1002/ehf.497>
- Brouwers FP, de Boer RA, van der Harst P, Voors AA, Gansevoort RT, Bakker SJ, et al. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. *Eur Heart J*. 2013;34:1424–1431. <https://doi.org/10.1093/eurheartj/ehs066>
- Metra M, Cotter G, Gheorghide M, Dei Cas L, Voors AA. The role of the kidney in heart failure. *Eur Heart J*. 2012;33:2135–2142. <https://doi.org/10.1093/eurheartj/ehs205>
- de Boer RA, Nayor M, DeFilippi CR, Enserro D, Bhamhani V, Kizer JR, et al. Association of cardiovascular biomarkers with incident heart failure with preserved and reduced ejection fraction. *JAMA Cardiol*. 2018;3:215–224. <https://doi.org/10.1001/jamacardio.2017.4987>
- Gansevoort RT, Brinkman J, Bakker SJL, De Jong PE, De Zeeuw D. Evaluation of measures of urinary albumin excretion. *Am J Epidemiol*. 2006;164:725–727. <https://doi.org/10.1093/aje/kwj271>
- Pasternack A, Kuhlback B. Diurnal variations of serum and urine creatine and creatinine. *Scand J Clin Lab Invest*. 1971;27:1–7. <https://doi.org/10.3109/00365517109080181>
- Naresh CN, Hayen A, Weening A, Craig JC, Chadban SJ. Day-to-day variability in spot urine albumin-creatinine ratio. *Am J Kidney Dis*. 2013;62:1095–1101. <https://doi.org/10.1053/j.ajkd.2013.06.016>
- Hillege HL, Fidler V, Diercks GFH, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al. Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. *Circulation*. 2002;106:1777–1782. <https://doi.org/10.1161/01.cir.0000031732.78052.81>
- CBS. Statistics Netherlands. <http://www.cbs.nl/en-BG/>. Accessed 20 February 2013.
- Paulus WJ, Tschöpe C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, et al. How to diagnose diastolic heart failure: A consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of

- Cardiology. *Eur Heart J*. 2007;**28**:2539–2550. <https://doi.org/10.1093/eurheartj/ehm037>
19. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail*. 2012;**14**:803–869. <https://doi.org/10.1093/eurjhf/hfs105>
 20. Nagin DS, Odgers CL. Group-based trajectory modeling in clinical research. *Annu Rev Clin Psychol*. 2010;**6**:109–138. <https://doi.org/10.1146/annurev.clinpsy.121208.131413>
 21. Kao DP, Lewsey JD, Anand IS, Massie BM, Zile MR, Carson PE, et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. *Eur J Heart Fail*. 2015;**17**:925–935. <https://doi.org/10.1002/ehf.327>
 22. Ferreira JP, Duarte K, McMurray JJV, Pitt B, van Veldhuisen DJ, Vincent J, et al. Data-driven approach to identify subgroups of heart failure with reduced ejection fraction patients with different prognoses and aldosterone antagonist response patterns. *Circ Heart Fail*. 2018;**11**:e004926. <https://doi.org/10.1161/CIRCHEARTFAILURE.118.004926>
 23. Tromp J, Tay WT, Ouwkerk W, Teng THK, Yap J, MacDonald MR, et al. Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry. *PLoS Med*. 2018;**15**:e1002541. <https://doi.org/10.1371/journal.pmed.1002541>
 24. Tein JY, Coxe S, Cham H. Statistical power to detect the correct number of classes in latent profile analysis. *Struct Equ Modeling*. 2013;**20**:640–657. <https://doi.org/10.1080/10705511.2013.824781>
 25. Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. *Circulation*. 2016;**133**:601–609. <https://doi.org/10.1161/CIRCULATIONAHA.115.017719>
 26. Tromp J, Paniagua SMA, Lau ES, Allen NB, Blaha MJ, Gansevoort RT, et al. Age dependent associations of risk factors with heart failure: Pooled population based cohort study. *BMJ*. 2021;**372**:n461. <https://doi.org/10.1136/bmj.n461>
 27. Ho JE, Enserro D, Brouwers FP, Kizer JR, Shah SJ, Psaty BM, et al. Predicting heart failure with preserved and reduced ejection fraction: The international collaboration on heart failure subtypes. *Circ Heart Fail*. 2016;**9**:e003116. <https://doi.org/10.1161/CIRCHEARTFAILURE.115.003116>
 28. Patel RB, Colangelo LA, Reis JP, Lima JAC, Shah SJ, Lloyd-Jones DM. Association of longitudinal trajectory of albuminuria in young adulthood with myocardial structure and function in later life: Coronary Artery Risk Development in Young Adults (CARDIA) study. *JAMA Cardiol*. 2020;**5**:184–192. <https://doi.org/10.1001/jamacardio.2019.4867>
 29. Naylor M, Larson MG, Wang N, Santhanakrishnan R, Lee DS, Tsao CW, et al. The association of chronic kidney disease and microalbuminuria with heart failure with preserved vs. reduced ejection fraction. *Eur J Heart Fail*. 2017;**19**:615–623. <https://doi.org/10.1002/ehf.778>
 30. ter Maaten JM, Voors AA, Damman K, van der Meer P, Anker SD, Cleland JG, et al. Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure. *Int J Cardiol*. 2018;**253**:84–90. <https://doi.org/10.1016/j.ijcard.2017.10.010>
 31. Vaduganathan M, Pareek M, Kristensen AMD, Biering-Sørensen T, Byrne C, Almarzooq Z, et al. Prevention of heart failure events with intensive versus standard blood pressure lowering across the spectrum of kidney function and albuminuria: A SPRINT substudy. *Eur J Heart Fail*. 2021;**23**:384–392. <https://doi.org/10.1002/ehf.1971>
 32. Berg DD, Wiviott SD, Scirica BM, Gurmu Y, Mosenzon O, Murphy SA, et al. Heart failure risk stratification and efficacy of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus. *Circulation*. 2019;**140**:1569–1577. <https://doi.org/10.1161/CIRCULATIONAHA.119.042685>